Transform Your Portfolio With This Simple Morning Trade!

Hi, I’m trading expert Dave Aquino and I want to show you how to take advantage of a trading opportunity happening nearly every morning at 9:30 EST.

My free guide, “How To Master The Retirement Trade” will show you exactly why traders in the know want to keep this trade a secret.

Donald A. Zakrowski net worth and biography

Donald Zakrowski Biography and Net Worth

CAO of Eli Lilly and Company

The estimated Net Worth of Donald A Zakrowski is at least $3.57 Million dollars as of 28 April 2021. Mr Zakrowski owns over 3,000 units of Lilly(Eli) & Co stock worth over $1,332,287 and over the last 9 years he sold LLY stock worth over $2,241,355.

Mr has made over 18 trades of the Lilly(Eli) & Co stock since 2012, according to the Form 4 filled with the SEC. Most recently he sold 3,000 units of LLY stock worth $544,140 on 28 April 2021.

The largest trade he's ever made was selling 3,700 units of Lilly(Eli) & Co stock on 2 March 2020 worth over $473,600. On average, Mr trades about 896 units every 106 days since 2012. As of 28 April 2021 he still owns at least 5,987 units of Lilly(Eli) & Co stock.

What is Donald A. Zakrowski's net worth?: The estimated net worth of Donald A. Zakrowski is at least $2.96 million as of August 21st, 2023. Mr. Zakrowski owns 5,378 shares of Eli Lilly and Company stock worth more than $2,960,804 as of September 23rd. This net worth estimate does not reflect any other investments that Mr. Zakrowski may own. Learn More about Donald A. Zakrowski's net worth.
How do I contact Donald A. Zakrowski?: The corporate mailing address for Mr. Zakrowski and other Eli Lilly and Company executives is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. Eli Lilly and Company can also be reached via phone at (317) 276-2000 and via email at [email protected]. Learn More on Donald A. Zakrowski's contact information.
Has Donald A. Zakrowski been buying or selling shares of Eli Lilly and Company?: Within the last three months, Donald A. Zakrowski has sold $327,906.00 in Eli Lilly and Company stock. Most recently, Donald A. Zakrowski sold 600 shares of the business's stock in a transaction on Monday, August 21st. The shares were sold at an average price of $546.51, for a transaction totalling $327,906.00. Following the completion of the sale, the chief accounting officer now directly owns 5,378 shares of the company's stock, valued at $2,939,130.78. Learn More on Donald A. Zakrowski's trading history.
Who are Eli Lilly and Company's active insiders?: Eli Lilly and Company's insider roster includes Anat Ashkenazi (Sr. VP & CFO ), Melissa Barnes (SVP), Enrique Conterno (SVP), Stephen Fry (SVP), Michael Harrington (VP), Susan Mahony (SVP), Johna Norton (EVP), Myles O'Neill (SVP), Derica Rice (EVP), David Ricks (CEO), Marschall Runge (Director), Aarti Shah (SVP), Christi Shaw (SVP), Jeffrey Simmons (SVP), Daniel Skovronsky (SVP), Joshua Smiley (CFO), Jackson Tai (Director), Jacob Van Naarden (Sr. VP), Alonzo Weems (SVP), Anne White (SVP), Ilya Yuffa (SVP), Donald Zakrowski (CAO), and Alfonso Zulueta (SVP). Learn More on Eli Lilly and Company's active insiders.
Are insiders buying or selling shares of Eli Lilly and Company?: In the last year, Eli Lilly and Company insiders bought shares 1 times. They purchased a total of 29,992,668 shares worth more than $374,908,350.00. In the last year, insiders at the sold shares 41 times. They sold a total of 2,974,300 shares worth more than $21,822,710,171.39. The most recent insider tranaction occured on September, 12th when EVP Alonzo Weems sold 1,148 shares worth more than $678,445.04. Insiders at Eli Lilly and Company own 0.1% of the company. Learn More about insider trades at Eli Lilly and Company.
Information on this page was last updated on 9/12/2023.

Donald A. Zakrowski Insider Trading History at Eli Lilly and Company

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/21/2023	Sell	600	$546.51	$327,906.00	5,378
5/15/2023	Sell	600	$435.29	$261,174.00	5,978
6/1/2022	Sell	1,000	$313.44	$313,440.00	6,274
2/25/2022	Sell	1,660	$243.84	$404,774.40
4/28/2021	Sell	3,000	$181.38	$544,140.00	5,987
3/22/2019	Sell	1,000	$128.50	$128,500.00
3/1/2019	Sell	1,000	$127.01	$127,010.00
9/4/2018	Sell	600	$105.57	$63,342.00	3,530
3/1/2018	Sell	860	$76.50	$65,790.00
2/21/2018	Sell	876	$77.55	$67,933.80	4,130
2/5/2018	Sell	900	$81.09	$72,981.00	4,130
2/2/2017	Sell	2,000	$77.52	$155,040.00	886
7/28/2016	Sell	1,213	$83.16	$100,873.08	1,300
5/2/2016	Sell	1,600	$75.86	$121,376.00	3,113

Donald A. Zakrowski Buying and Selling Activity at Eli Lilly and Company

Eli Lilly and Company Company Overview

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Today's Range

Now: $550.54

$547.63

$555.49

50 Day Range

MA: $524.53

$447.14

$599.54

2 Week Range

Now: $550.54

$304.88

$601.84

Volume

2,354,187 shs

Average Volume

2,756,032 shs

Market Capitalization

$522.62 billion

P/E Ratio

76.57

Dividend Yield

0.82%

Beta

0.32

Laser breakthrough could send stock soaring 2,467%

From Behind the Markets | Ad

Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...

Here's the next stock we think soars >>>